Endometrial Cancer: What Is New in Adjuvant and Molecularly Targeted Therapy?
Endometrial cancer is the most common gynaecological cancer in western countries. Radiotherapy remains the mainstay of postoperative management, but accumulating data show that adjuvant chemotherapy may display promising results after staging surgery. The prognosis of patients with metastatic diseas...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2010-01-01
|
| Series: | Obstetrics and Gynecology International |
| Online Access: | http://dx.doi.org/10.1155/2010/749579 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850166453190262784 |
|---|---|
| author | Flora Zagouri George Bozas Eftichia Kafantari Marinos Tsiatas Nikitas Nikitas Meletios-A. Dimopoulos Christos A. Papadimitriou |
| author_facet | Flora Zagouri George Bozas Eftichia Kafantari Marinos Tsiatas Nikitas Nikitas Meletios-A. Dimopoulos Christos A. Papadimitriou |
| author_sort | Flora Zagouri |
| collection | DOAJ |
| description | Endometrial cancer is the most common gynaecological cancer in western countries. Radiotherapy remains the mainstay of postoperative management, but accumulating data show that adjuvant chemotherapy may display promising results after staging surgery. The prognosis of patients with metastatic disease remains disappointing with only one-year survival. Progestins represent an effective option, especially for those patients with low-grade estrogen and/or progesterone receptor positive disease. Chemotherapy using the combination of paclitaxel, doxorubicin, and cisplatin is beneficial for patients with advanced or metastatic disease after staging surgery and potentially for patients with early-stage disease and high-risk factors. Toxicity is a point in question; however, the combination of paclitaxel with carboplatin may diminish these concerns. In women with multiple medical comorbidities, single-agent chemotherapy may be better tolerated with acceptable results. Our increased knowledge of the molecular aspects of endometrial cancer biology has paved the way for clinical research to develop novel targeted antineoplastic agents (everolimus, temsirolimus, gefitinib, erlotinib, cetuximab, trastuzumab, bevacizumab, sorafenib) as more effective and less toxic options. Continued investigation into the molecular pathways of endometrial cancer development and progression will increase our knowledge of this disease leading to the discovery of novel, superior agents. |
| format | Article |
| id | doaj-art-d9c93d240c224993bcadbef0165511e5 |
| institution | OA Journals |
| issn | 1687-9589 1687-9597 |
| language | English |
| publishDate | 2010-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Obstetrics and Gynecology International |
| spelling | doaj-art-d9c93d240c224993bcadbef0165511e52025-08-20T02:21:25ZengWileyObstetrics and Gynecology International1687-95891687-95972010-01-01201010.1155/2010/749579749579Endometrial Cancer: What Is New in Adjuvant and Molecularly Targeted Therapy?Flora Zagouri0George Bozas1Eftichia Kafantari2Marinos Tsiatas3Nikitas Nikitas4Meletios-A. Dimopoulos5Christos A. Papadimitriou6Department of Clinical Therapeutics, “Alexandra” Hospital, School of Medicine, University of Athens, Athens, GreeceDepartment of Clinical Therapeutics, “Alexandra” Hospital, School of Medicine, University of Athens, Athens, GreeceDepartment of Clinical Therapeutics, “Alexandra” Hospital, School of Medicine, University of Athens, Athens, GreeceDepartment of Clinical Therapeutics, “Alexandra” Hospital, School of Medicine, University of Athens, Athens, GreeceDepartment of Clinical Therapeutics, “Alexandra” Hospital, School of Medicine, University of Athens, Athens, GreeceDepartment of Clinical Therapeutics, “Alexandra” Hospital, School of Medicine, University of Athens, Athens, GreeceDepartment of Clinical Therapeutics, “Alexandra” Hospital, School of Medicine, University of Athens, Athens, GreeceEndometrial cancer is the most common gynaecological cancer in western countries. Radiotherapy remains the mainstay of postoperative management, but accumulating data show that adjuvant chemotherapy may display promising results after staging surgery. The prognosis of patients with metastatic disease remains disappointing with only one-year survival. Progestins represent an effective option, especially for those patients with low-grade estrogen and/or progesterone receptor positive disease. Chemotherapy using the combination of paclitaxel, doxorubicin, and cisplatin is beneficial for patients with advanced or metastatic disease after staging surgery and potentially for patients with early-stage disease and high-risk factors. Toxicity is a point in question; however, the combination of paclitaxel with carboplatin may diminish these concerns. In women with multiple medical comorbidities, single-agent chemotherapy may be better tolerated with acceptable results. Our increased knowledge of the molecular aspects of endometrial cancer biology has paved the way for clinical research to develop novel targeted antineoplastic agents (everolimus, temsirolimus, gefitinib, erlotinib, cetuximab, trastuzumab, bevacizumab, sorafenib) as more effective and less toxic options. Continued investigation into the molecular pathways of endometrial cancer development and progression will increase our knowledge of this disease leading to the discovery of novel, superior agents.http://dx.doi.org/10.1155/2010/749579 |
| spellingShingle | Flora Zagouri George Bozas Eftichia Kafantari Marinos Tsiatas Nikitas Nikitas Meletios-A. Dimopoulos Christos A. Papadimitriou Endometrial Cancer: What Is New in Adjuvant and Molecularly Targeted Therapy? Obstetrics and Gynecology International |
| title | Endometrial Cancer: What Is New in Adjuvant and Molecularly Targeted Therapy? |
| title_full | Endometrial Cancer: What Is New in Adjuvant and Molecularly Targeted Therapy? |
| title_fullStr | Endometrial Cancer: What Is New in Adjuvant and Molecularly Targeted Therapy? |
| title_full_unstemmed | Endometrial Cancer: What Is New in Adjuvant and Molecularly Targeted Therapy? |
| title_short | Endometrial Cancer: What Is New in Adjuvant and Molecularly Targeted Therapy? |
| title_sort | endometrial cancer what is new in adjuvant and molecularly targeted therapy |
| url | http://dx.doi.org/10.1155/2010/749579 |
| work_keys_str_mv | AT florazagouri endometrialcancerwhatisnewinadjuvantandmolecularlytargetedtherapy AT georgebozas endometrialcancerwhatisnewinadjuvantandmolecularlytargetedtherapy AT eftichiakafantari endometrialcancerwhatisnewinadjuvantandmolecularlytargetedtherapy AT marinostsiatas endometrialcancerwhatisnewinadjuvantandmolecularlytargetedtherapy AT nikitasnikitas endometrialcancerwhatisnewinadjuvantandmolecularlytargetedtherapy AT meletiosadimopoulos endometrialcancerwhatisnewinadjuvantandmolecularlytargetedtherapy AT christosapapadimitriou endometrialcancerwhatisnewinadjuvantandmolecularlytargetedtherapy |